Recent advances in natriuretic peptides in congestive heart failure

Guido Boerrigter; John C. Burnett

doi:10.1517/13543784.13.6.643

Recent advances in natriuretic peptides in congestive heart failure

Guido Boerrigter, John C. Burnett

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

65 Scopus citations

Abstract

Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004

Original language	English (US)
Pages (from-to)	643-652
Number of pages	10
Journal	Expert Opinion on Investigational Drugs
Volume	13
Issue number	6
DOIs	https://doi.org/10.1517/13543784.13.6.643
State	Published - Jun 2004

Keywords

Cyclic guanosine monophosphate
Heart failure
Natriuretic peptides
Nesiritide
Neurohumoral activation

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1517/13543784.13.6.643

Cite this

@article{0e34769551e94afe86cce57d85cbabf8,

title = "Recent advances in natriuretic peptides in congestive heart failure",

abstract = "Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004",

keywords = "Cyclic guanosine monophosphate, Heart failure, Natriuretic peptides, Nesiritide, Neurohumoral activation",

author = "Guido Boerrigter and Burnett, {John C.}",

note = "Funding Information: This research was supported by grants HL-36634 from the National Institutes of Health, the Miami Heart Research Institute, the Mayo Foundation, the Marriott Foundation and an Unrestricted Grant for Cardiovascular Research from Bristol-Myers Squibb.",

year = "2004",

month = jun,

doi = "10.1517/13543784.13.6.643",

language = "English (US)",

volume = "13",

pages = "643--652",

journal = "Expert Opinion on Investigational Drugs",

issn = "1354-3784",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Recent advances in natriuretic peptides in congestive heart failure

AU - Boerrigter, Guido

AU - Burnett, John C.

N1 - Funding Information: This research was supported by grants HL-36634 from the National Institutes of Health, the Miami Heart Research Institute, the Mayo Foundation, the Marriott Foundation and an Unrestricted Grant for Cardiovascular Research from Bristol-Myers Squibb.

PY - 2004/6

Y1 - 2004/6

N2 - Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004

AB - Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed. 2004

KW - Cyclic guanosine monophosphate

KW - Heart failure

KW - Natriuretic peptides

KW - Nesiritide

KW - Neurohumoral activation

UR - http://www.scopus.com/inward/record.url?scp=3042847645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042847645&partnerID=8YFLogxK

U2 - 10.1517/13543784.13.6.643

DO - 10.1517/13543784.13.6.643

M3 - Review article

C2 - 15174950

AN - SCOPUS:3042847645

SN - 1354-3784

VL - 13

SP - 643

EP - 652

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

IS - 6

ER -

Recent advances in natriuretic peptides in congestive heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this